Table 1. Clinical characteristics of the study population and response to r-hGH defined by SDE groups.
| GHD (n=118) | Low SDE ⩽14.3 h | Intermediate SDE SDE >15.5 to <14.3 h | High SDE ⩾15.5 h | P-value |
|---|---|---|---|---|
| Number of patients (n) | 23 | 73 | 22 | |
| Gender (M/F) | 15/8 | 47/26 | 13/9 | 0.888 |
| BW SDS | −0.5 (−1.3, 0.8) | −0.5 (−1.3, 0.5) | −0.5 (−0.9, 0.1) | 0.883 |
| At baseline | ||||
| GH peak response (μg l−1) | 4.5 (3.0, 6.2) | 4.0 (2.3, 5.5) | 3.8 (1.2, 5.3) | 0.331 |
| Age (years) | 8.9 (6.2, 11.5) | 9.1 (7.3, 11.5) | 8.0 (5.0, 11.0) | 0.120 |
| Height SDS | −2.0 (−2.4, −1.6) | −2.3 (−2.8, −1.8) | −2.1 (−2.8, −1.6) | 0.066 |
| BMI SDS | −0.1 (−0.8, 1.6) | −0.3 (−1.1, 0.6) | −0.7 (−1.6, 0.1) | 0.090 |
| TH SDS | −1.6 (−2.3, −0.5) | −0.9 (−1.7, −0.3) | −0.1 (−1.1, 0.7) | 0.002 |
| Distance to TH SDS | −0.6 (−1.3, 0.6) | −1.3 (−2.2, −0.6) | −2.1 (−3.2, −1.3) | <0.0001 |
| Average r-hGH dose (mg kg−1) | 0.03 (0.030, 0.036) | 0.03 (0.031, 0.035) | 0.03 (0.030, 0.035) | 0.263 |
| 1-year visit | ||||
| HV (cm per year) | 8.2 (7.0, 10.3) | 8.1 (7.0, 9.8) | 9.8 (8.5, 11.4) | 0.019 |
| HV SDS | 2.0 (0.5, 4.0) | 1.8 (0.5, 3.2) | 3.0 (1.4, 6.8) | 0.024 |
| Δ Height SDS | 0.6 (0.3, 1.0) | 0.6 (0.3, 0.9) | 0.8 (0.6, 1.4) | 0.017 |
| Δ BMI SDS | 0.1 (−0.2, 0.6) | −0.1 (−0.4, 0.2) | −0.1 (−0.3, 0.2) | 0.143 |
| Puberty onset (%) | 7/23 (30%) | 20/73 (27%) | 4/22 (18%) | 0.607 |
Abbreviations: BMI, body mass index; BW, birth weight; Δ, delta; GH, growth hormone; HV; height velocity; r-hGH, recombinant human GH; SDS, s.d. score; TH, target height. Data are number or median (Q1, Q3). P-value: low vs intermediate vs high SDE.